The use of verapamil, a calcium channel antagonist, to circumvent established resistance in human cancer cell lines has been reported for lung (Fetherston et al., 1985) and ovary (Rogan et al., 1984) using adriamycin and the vinca alkaloids. We were interested in its potential use for the enhancement of cytotoxicity of vindesine and cisplatinum in non-small cell cancer of lung (NSCCL). An earlier study (Simmonds et al., 1986) using primary patient material in clonogenic assay has confirmed the overall poor clinical response rates to these drugs reported by Elliott et al. (1984).In this study, 18 lung tumour samples, 17 squamous and 1 adenocarcinoma, were removed at thoracotomy of previously untreated patients and grown in the bilayered agar clonogenic assay system. In brief, samples were mechanically disaggregated with crossed scalpels in Hanks balanced salt solution (HBSS) with penicillin and streptomycin and resulting cell suspensions passed through needles of decreasing gauge to obtain single cells. Tumour cells obtained were suspended in RPM1-1640+10% FBS and aliquots of 106 viable cells were exposed for 1 h at 37°C to concentrations representing 10% of the peak plasma concentration for cis-platinum (0.25 pg ml -1) and vindesine (0.02 pgml-1) (Alberts et al., 1980) Figure 1 shows the response to cis-platinum. All specimens except no. 13 were resistant in vitro when tested alone, the degree of resistance varying from moderate to very marked. Fourteen of the 18 patients demonstrated greater than 70% survival following treatment with this drug. In the presence of verapamil, only one patient, number 8, showed a change to sensitivity from 60% to 36% survival. Patient 13 had sensitivity changed to resistance while samples number 7, 11, 12, 17 and 18 demonstrated increased resistance. A change in the degree of resistance was observed for patients 2, 4, 5, 6, 9, 10, 14, and 15; this was lessened while specimens from patients 1, 3 and 16 were unaffected. Plating efficiencies in every case were sufficiently high for these drug results to be significant (11/18PE>0.03%) and the treatment of cells with verapamil alone produced no cytotoxic effects (figures not shown). Figure 2 shows the response to vindesine. In the absence of verapamil all samples were resistant and 10/18 patients exhibited greater than 70% survival following treatment with this drug. Pronounced changes, however, were observed in vindesine response in the presence of verapamil for 7 samples; patient numbers, 2, 5, 6, 7, 8 and 13 became
Summary Lung tumours of non small cell pathology were cultured by clonogenic assay in several media. Culture was successful in spleen conditioned medium, but only 57% grew and low plating efficiencies (PE) meant that only 23% of the original number produced significant drug results. Comparison of rat erythrocyte lysate (REL) medium with serum free defined medium (HITES) and HITES +10% FBS demonstrated clear enhancement of PE in REL although growth was 100% successful in all these media. Ninety-three percent of samples tested against drugs in REL produced significant results. A later comparison of REL with McCoy's SA+rbc+hydrocortisone produced relatively poor culture success for these 3 media and equivocal growth patterns. Low PE was attributed to age of rats used for rbc. Vindesine and cis-platinum cytotoxicity in spleen conditioned medium were 61% and 15% sensitivity respectively. These do not concur with clinical experience but the figures for overt resistance, at 39% and 69%, correspond with expected non-responders to these regimes. Drug testing in REL produced figures correlating more closely with clinical performance at 45% sensitivity to platinum and 36% of patients sensitive to both drugs, but the vindesine sensitivity at 55% is again discrepant with performance of this drug as a single agent.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.